Expression and effect of CXCL14 in colorectal carcinoma

Lin,Kezhi; Zou,Ruanmin; Lin,Feng; Zheng,Shuang; Shen,Xian; Xue,Xiangyang

doi:10.3892/mmr.2014.2343

Expression and effect of CXCL14 in colorectal carcinoma

Authors:
- Kezhi Lin
- Ruanmin Zou
- Feng Lin
- Shuang Zheng
- Xian Shen
- Xiangyang Xue
View Affiliations

Affiliations: Experimental Teaching Center, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of General Surgery, Taizhou First People's Hospital, Taizhou, Zhejiang 318020, P.R. China, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: June 17, 2014 https://doi.org/10.3892/mmr.2014.2343
Pages: 1561-1568

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemokines are important in the proliferation and metastasis of tumors. CXCL14 is a member of the CXCL chemokine family and exhibits various expression patterns in different types of tumor, even those tumors that occur in the same type of tissue. The expression of CXCL14 and its clinical significance in colorectal carcinoma are unclear. In the present study, the expression levels of CXCL14 in colorectal carcinoma and adjacent normal tissues were detected using reverse transcription-quantitative polymerase chain reaction and immunohistochemistry. Kaplan‑Meier survival curves and the Cox regression model were applied to evaluate the clinical significance of the expression levels of CXCL14 in colorectal carcinoma compared with those in normal tissues. To investigate the effects at a cellular level, a replication‑defective lentivirus overexpressing CXCL14 was constructed and transfected into HT29 colorectal carcinoma cells. The effect of CXCL14 on the proliferation of colorectal carcinoma cells and the change in cell cycle distributions were investigated using a cell counting kit‑8 assay and flow cytometry, respectively. Results of the current study indicated that the expression levels of CXCL14 mRNA and protein in colorectal carcinoma were markedly reduced compared with levels in normal tissues (P<0.05). The clinical correlation analysis suggested that downregulation of CXCL14 expression in tumors was associated with lymph metastasis, tumor location, and clinicopathological stage (P<0.05). Kaplan‑Meier survival analysis revealed that downregulation of CXCL14 expression was correlated with a poor prognosis (P<0.01). Overexpression of CXCL14 by lentiviral transfection produced an inhibitory effect on cell proliferation by arresting the cell cycle in the G1 stage. The data of the current study suggest that CXCL14 may be involved in the development and progression of colorectal carcinoma, and may act directly as a potential cancer suppressor gene. The level of CXCL14 expression may be a valuable adjuvant parameter in predicting the prognosis of colorectal carcinoma and may be a potential therapeutic target.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Devaud C, John LB, Westwood JA, Darcy PK and Kershaw MH: Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2:e259612013. View Article : Google Scholar : PubMed/NCBI
3	Allen SJ, Crown SE and Handel TM: Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 25:787–820. 2007. View Article : Google Scholar : PubMed/NCBI
4	Mellado M, Rodríguez-Frade JM, Mañes S and Martínez AC: Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol. 19:397–421. 2001. View Article : Google Scholar : PubMed/NCBI
5	Sallusto F, Mackay CR and Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 18:593–620. 2000. View Article : Google Scholar : PubMed/NCBI
6	Ruffini PA, Morandi P, Cabioglu N, Altundag K and Cristofanilli M: Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer. 109:2392–2404. 2007. View Article : Google Scholar : PubMed/NCBI
7	Mantovani A, Savino B, Locati M, Zammataro L, Allavena P and Bonecchi R: The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 21:27–39. 2010. View Article : Google Scholar
8	Uchida H, Iwashita Y, Sasaki A, Shibata K, Matsumoto T, Ohta M and Kitano S: Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol. 21:161–168. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C and Keilholz U: Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol. 24:1910–1916. 2006. View Article : Google Scholar : PubMed/NCBI
10	Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, et al: High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 67:4725–4731. 2007. View Article : Google Scholar : PubMed/NCBI
11	Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K II, Azam M and Hou YH: Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun. 255:703–706. 1999. View Article : Google Scholar : PubMed/NCBI
12	Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK and Clayman GL: In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol. 156:1937–1950. 2000. View Article : Google Scholar : PubMed/NCBI
13	Meuter S and Moser B: Constitutive expression of CXCL14 in healthy human and murine epithelial tissues. Cytokine. 44:248–255. 2008. View Article : Google Scholar : PubMed/NCBI
14	Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K and Hromas R: The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol. 34:1101–1105. 2006. View Article : Google Scholar : PubMed/NCBI
15	Juremalm M and Nilsson G: Chemokine receptor expression by mast cells. Chem Immunol Allergy. 87:130–144. 2005. View Article : Google Scholar : PubMed/NCBI
16	Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-Naggar AK, Roberts D, et al: BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 64:8262–8270. 2004. View Article : Google Scholar : PubMed/NCBI
17	Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, Watson JD and Kumble KD: B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int Immunol. 12:677–689. 2000. View Article : Google Scholar : PubMed/NCBI
18	Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I and Moser B: Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 194:855–861. 2001. View Article : Google Scholar
19	Hara T and Nakayama Y: CXCL14 and insulin action. Vitam Horm. 80:107–123. 2009. View Article : Google Scholar
20	Tanegashima K, Okamoto S, Nakayama Y, Taya C, Shitara H, Ishii R, Yonekawa H, Minokoshi Y and Hara T: CXCL14 deficiency in mice attenuates obesity and inhibits feeding behavior in a novel environment. PLoS One. 5:e103212010. View Article : Google Scholar : PubMed/NCBI
21	Maerki C, Meuter S, Liebi M, Muhlemann K, Frederick MJ, Yawalkar N, Moser B and Wolf M: Potent and broad-spectrum antimicrobial activity of CXCL14 suggests an immediate role in skin infections. J Immunol. 182:507–514. 2009. View Article : Google Scholar : PubMed/NCBI
22	Lindberg J, af Klint E, Catrina AI, Nilsson P, Klareskog L, Ulfgren AK and Lundeberg J: Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther. 8:R1792006. View Article : Google Scholar : PubMed/NCBI
23	Hara T and Tanegashima K: Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals. J Biochem. 151:469–476. 2012. View Article : Google Scholar : PubMed/NCBI
24	Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L and Belinsky SA: Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene. 29:5159–5170. 2010. View Article : Google Scholar : PubMed/NCBI
25	Gu XL, Ou ZL, Lin FJ, Yang XL, Luo JM, Shen ZZ and Shao ZM: Expression of CXCL14 and its anticancer role in breast cancer. Breast Cancer Res Treat. 135:725–735. 2012. View Article : Google Scholar : PubMed/NCBI
26	Ozawa S, Kato Y, Ito S, Komori R, Shiiki N, Tsukinoki K, Ozono S, Maehata Y, et al: Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer Sci. 100:2202–2209. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hu C, Lin F, Zhu G, Xue X, Ding Y, Zhao Z, Zhang L and Shen X: Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer. Int J Oncol. 43:1487–1494. 2013.PubMed/NCBI
28	Wang W, Huang P, Zhang L, Wei J, Xie Q, Sun Q, Zhou X, Xie H, Zhou L and Zheng S: Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 104:1523–1531. 2013. View Article : Google Scholar : PubMed/NCBI
29	Song EY, Shurin MR, Tourkova IL, Gutkin DW and Shurin GV: Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Res. 70:4394–4401. 2010. View Article : Google Scholar : PubMed/NCBI
30	Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L and Ostman A: CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA. 106:3414–3419. 2009. View Article : Google Scholar : PubMed/NCBI
31	Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Büchler MW and Friess H: CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 259:209–217. 2008. View Article : Google Scholar : PubMed/NCBI
32	Zeng J, Yang X, Cheng L, Liu R, Lei Y, Dong D, Li F, Lau QC, et al: Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med. 11:62013. View Article : Google Scholar : PubMed/NCBI
33	Cao B, Yang Y, Pan Y, Jia Y, Brock MV, Herman JG and Guo M: Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion. Discov Med. 16:137–147. 2013.PubMed/NCBI
34	Winawer SJ, Krabshuis J, Lambert R, O’Brien M and Fried M; World Gastroenterology Organization Guidelines Committee. Cascade colorectal cancer screening guidelines: a global conceptual model. J Chin Gastroenterol. 45:297–300. 2011. View Article : Google Scholar : PubMed/NCBI
35	Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al: Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 11:519–528. 2013.PubMed/NCBI
36	Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity. 12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
37	Campanelli AP, Brodskyn CI, Boaventura V, Silva C, Roselino AM, Costa J, Saldanha AC, de Freitas LA, et al: Chemokines and chemokine receptors coordinate the inflammatory immune response in human cutaneous leishmaniasis. Hum Immunol. 71:1220–1227. 2010. View Article : Google Scholar : PubMed/NCBI
38	Wong MM and Fish EN: Chemokines: attractive mediators of the immune response. Semin Immunol. 15:5–14. 2003. View Article : Google Scholar : PubMed/NCBI
39	Moser B, Wolf M, Walz A and Loetscher P: Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25:75–84. 2004. View Article : Google Scholar : PubMed/NCBI
40	Krieg C and Boyman O: The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin Cancer Biol. 19:76–83. 2009. View Article : Google Scholar : PubMed/NCBI
41	Balkwill FR: The chemokine system and cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar
42	Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11:597–606. 2011. View Article : Google Scholar : PubMed/NCBI
43	Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, Collins B, Chatta GS and Shurin MR: Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 174:5490–5498. 2005. View Article : Google Scholar
44	Izukuri K, Suzuki K, Yajima N, Ozawa S, Ito S, Kubota E and Hata R: Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants [corrected]. Transgenic Res. 19:1109–1117. 2010.PubMed/NCBI
45	Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 6:17–32. 2004. View Article : Google Scholar : PubMed/NCBI